1800 244 735

Huntington’s Disease research update

Handwriting Can Help Identify Asymptomatic Huntington’s, Study Suggests.

WORDS Alberto Molano, PhD from Huntington’s Disease News

ANALYSIS OF handwriting movements using a pen tablet and specialised software can accurately distinguish  people with Huntington’s disease who are still asymptomatic from those without the disease, a new study suggests.

The findings also reveal that certain stroke  features  differ significantly between healthy individuals and patients who are already experiencing Huntington’s symptoms.

The research, “Handwriting Movement abnormalities in Symptomatic and premanifest huntington’s Disease,” was published in the journal Movement Disorders Clinical Practice.

Handwriting abnormalities in huntington’s patients were last reported nearly 20 years ago, and included longer stroke duration and greater variability in stroke velocity. among questions still unanswered is whether assessing handwriting movements can help detect abnormalities in the asymptomatic (premanifest) stage of Huntington’s and serve as a predictor of disease progression.

To investigate, researchers at university of California San Diego test- ed whether handwriting abnormalities were associated with clinical features in symptomatic patients, and if such abnormalities could distinguish asymptomatic Huntington’s patients from healthy controls.

The team asked participants to complete five simple tasks: draw simple loops left to right (a string of “l” letters in cursive writing), complex loops (“lleel- lee”), rapid overlay circles, and spirals, and write the  sentence “today is a nice day.”

Participants used a Wacom digitizing  tablet,  a  device  often used by artists to draw on a computer  screen.  the  tablet  has  a special pen and is sensitive to the level of applied pressure, mimicking traditional drawing on paper. Handwriting traces were recorded and analyzed using a specialized software called MovAlyzeR.

The study involved 38 symptomatic patients (mean age of 55 years), 30 asymptomatic individuals at risk for symptomatic disease (45 years), and 25 healthy controls (44 years).

Results revealed significantly longer and more variable stroke du- ration, as well as decreased hand- writing smoothness, and increased and more variable pen pressures in the handwriting of Huntington’s patients compared with the handwriting of the healthy controls.

Longer stroke duration was associated with greater penney burden of pathology (BOP) and CAG × age product, two measures of disease progression. Of note, the CAG × age product is calculated by multiplying the number of CAG repeats by the patient’s age.

CAG repeats are the genetic abnormality in people with huntington’s. Patients may have 36 to more than 120 of these repeats of three DNA building blocks (cytosine, adenine, and guanine) in their HTT gene. The longer this region is, the earlier the symptoms appear and the more severe the disease.

Handwriting abnormalities in Huntington’s patients were last reported nearly 20 years ago...

Data also showed that analysis of certain handwriting features could distinguish asymptomatic patients from controls with 85% accuracy, 90% sensitivity, and 80% specificity. these included greater variability in stroke amplitude, velocity and pen pressure, higher levels of pen pressure, longer stroke durations, and lower velocities for combinations of handwritten circles, sentences, and spirals.

“These findings support the clinical utility of dynamic measures of hand- writing kinematics as a potential early behavioral biomarker in [huntington’s],” the researchers wrote.

However, they cautioned that these results require confirmation, especially those in asymptomatic patients, and that studies in larger groups are still needed.

Latest Research Articles

Getting to the Root of Huntington's Disease: A Plant-Based Approach

Published date: 15 October, 2023

Researchers studied a fragment of the Huntington’s disease (HD) protein in plants and found a new way to stop it from forming toxic clumps. A special plant protein that the team identified can prevent harmful buildup in plants as well as in some HD model systems, showing potential for this approach as a possible way ... Read more

Could halting CAG expansions be a new treatment for HD?

Published date: 5 October, 2023

A recent paper from a group at UMass Chan Medical School, spearheaded by Dr. Daniel O'Reilly and led by Dr. Anastasia Khvorova, used genetic strategies to lower a protein other than huntingtin. This time the researchers went after a gene called MSH3. This is a gene that’s been getting a lot of attention in Huntington’s ... Read more

Tipping the balance; new insights into HD genetic modifiers

Published date: 1 September, 2023

Genetic modifiers can influence when HD symptoms begin. Some of these genes encode for different types of molecular machines whose normal job is to repair our DNA when it is broken or damaged. A recently published study from scientists at Thomas Jefferson University uncovers details of how these molecular machines help repair damaged DNA structures ... Read more

Drug to treat movement symptoms of HD approved by FDA

Published date: 22 August, 2023

The vast majority of people with Huntington’s disease experience movement symptoms known as chorea. Valbenazine, also known as INGREZZA, has recently been approved by the United States Food and Drug Administration (FDA), allowing doctors in the USA to prescribe this medicine for Huntington’s disease (HD) chorea. In this article we go through the key points ... Read more

Youthful competitors: young brain cells oust the old

Published date: 8 August, 2023

When you lose something, an easy solution can be to just replace it. But what if the something you’ve lost are cells in the brain? Can they simply be replaced? Some researchers have been working toward this for Huntington’s disease (HD) by injecting new cells into the brains of animal models. A recent publication that ... Read more

Updates from PTC Therapeutics and uniQure on their huntingtin-lowering trials

Published date: 21 June, 2023

On 21st June, both PTC Therapeutics and uniQure shared data from their respective clinical trials, both testing huntingtin-lowering as an approach to treat HD, but with different types of therapies. In this article we go through the data they each presented, what it all means and the next steps the companies will be taking. Treating ... Read more